Arvinas, Inc. (ARVN) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
ARVN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ARVN Revenue Analysis (2016–2025)
As of March 1, 2026, Arvinas, Inc. (ARVN) generated trailing twelve-month (TTM) revenue of $262.6 million, reflecting significant decline in growth of -84.0% year-over-year. The most recent quarter (Q4 2025) recorded $9.5 million in revenue, down 77.3% sequentially.
Looking at the longer-term picture, ARVN's 5-year compound annual growth rate (CAGR) stands at +58.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $263.4 million in 2024.
Revenue diversification analysis shows ARVN's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), ARVN has underperformed the peer group in terms of revenue growth. Compare ARVN vs REGN →
Peer Comparison
Compare ARVN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARVNCurrent | $263M | -84.0% | +58.9% | -45.1% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $262.6M | -0.3% | $-398,600,000 | -151.8% | $-118,500,000 | -45.1% |
| 2024 | $263.4M | +235.5% | $263.4M | 100.0% | $-250,200,000 | -95.0% |
| 2023 | $78.5M | -40.3% | $78.5M | 100.0% | $-401,500,000 | -511.5% |
| 2022 | $131.4M | +145.1% | $131.4M | 100.0% | $-263,200,000 | -200.3% |
| 2021 | $53.6M | +106.9% | $53.6M | 100.0% | $-188,400,000 | -351.5% |
| 2020 | $25.9M | -39.7% | $25.9M | 100.0% | $-120,800,000 | -466.4% |
| 2019 | $43.0M | +200.0% | $43.0M | 100.0% | $-51,524,514 | -119.9% |
| 2018 | $14.3M | +89.0% | $14.3M | 100.0% | $-43,802,078 | -305.8% |
| 2017 | $7.6M | +13.6% | $7.6M | 100.0% | $-24,760,267 | -326.7% |
| 2016 | $6.7M | - | $6.7M | 100.0% | $-16,469,420 | -247.0% |
See ARVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARVN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARVN vs AGIO
See how ARVN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARVN's revenue growth accelerating or slowing?
ARVN revenue declined -84.0% year-over-year, contrasting with the 5-year CAGR of +58.9%. TTM revenue fell to $263M. This reverses the prior growth trend.
What is ARVN's long-term revenue growth rate?
Arvinas, Inc.'s 5-year revenue CAGR of +58.9% reflects the variable expansion pattern. Current YoY growth of -84.0% is below this long-term average.
How is ARVN's revenue distributed by segment?
ARVN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.